Drugs and patents in ATC class B03AD - Iron in combination with folic acid

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
FOLVRON	ferrous sulfate; folic acid
>Tradename	>Generic Name

Last updated: June 27, 2026

ATC Class B03AD covers iron (alone) combined with folic acid products used for iron deficiency anemia with folate deficiency risk. The market is largely shaped by (1) long-established branded generics and established dosing regimens, (2) manufacturing and formulation patents that protect specific salts, ratios, and release characteristics, and (3) a small number of pending or late-expiring formulation and method-of-use rights in major jurisdictions. In the US, the competitive pathway is typically governed by ANDA submissions to FDA and any associated Orange Book listed patents; in the EU, market exclusivity and patent term extensions vary by country and marketing authorization history.

This document summarizes the patent and exclusivity logic that determines market entry for B03AD products and identifies the patent categories that most often constrain generic competition, the timelines that drive Paragraph IV or launch-readiness strategy, and the commercial dynamics that determine which products hold share.

What is ATC B03AD “iron in combination with folic acid” and how is it marketed?

Quick answer: B03AD products combine an iron salt with folic acid in fixed-dose combinations for anemia management, typically positioned around adherence, dosing simplicity, and prevention of folate deficiency in iron repletion regimens.

Which active ingredients typically fall under B03AD?

Most marketed products use:

Iron(II) salts (commonly ferrous sulfate, ferrous fumarate, or ferrous gluconate)
Folic acid (pteroylmonoglutamic acid)

Some products use different forms (for example, polymorphs or hydrates of iron salts), which can create separate formulation IP islands even when the actives match.

What dosage forms and strengths dominate?

Common commercial formats include:

Oral tablets (often once- or twice-daily)
Oral capsules
Oral liquids/syrups in pediatric and adherence-focused markets

Strength ranges are usually tied to elemental iron targets (for example, 60 to 120 mg elemental iron per day) and a fixed folate dose (often 0.5 to 1 mg/day). Specific ratios matter because they are repeatedly used in formulation claims.

How do branding and positioning affect patent value?

For B03AD, branded differentiation is often driven by:

dosing schedule convenience
tolerability profiles (GI adverse event mitigation)
pediatric palatability (liquid formulations)
stability and shelf-life in packaging

Those features translate into patent focus areas: coating, excipients, stabilization, and manufacturing method.

What patents protect iron plus folic acid combination products in major jurisdictions?

Quick answer: Protection most frequently comes from formulation patents (ratio, excipients, release profiles), manufacturing/process patents (granulation, coating, stabilization), and sometimes medical use patents (specific dosing regimens or indications). Composition-of-matter patents on folic acid and iron salts generally do not block generics because the actives are old and broadly known.

What patent types are most relevant for B03AD?

Formulation and composition patents
- fixed-dose ratio claims (iron salt to folic acid)
- particle size or polymorph of the iron salt
- specific excipient systems (binder, disintegrant, lubricant)
- coatings designed to reduce GI irritation or improve dissolution
Method-of-manufacture patents
- granulation processes and drying parameters
- coating and curing steps
- stabilization steps to reduce folate degradation
Method-of-use and dosing regimen patents
- specific patient subgroups (for example, pregnancy-adjacent anemia or malabsorption)
- structured titration schedules
- combinations with dietary supplements
Packaging and device-adjacent patents
- desiccant or moisture barrier packaging can appear in some estates when tied to stability testing and claims.

Where does the patent estate usually concentrate?

US: patents listed in FDA’s Orange Book usually cover the approved formulation and sometimes manufacturing methods. Generic entry risk depends on whether patents are listed, whether they expire, and whether an ANDA is ready for a design-around or a Paragraph IV decision.
EU: national/regional patent enforcement plus national SPC practice can matter, but B03AD rarely has blockbuster-style SPCs unless linked to a newer marketing authorization date and qualifying patent linkage.
UK/Canada/JP: similar logic with local enforcement and listing regimes; Japan’s patent landscape can differ in claim scope around formulation.

How many patents cover B03AD iron/folate products, and who are the recurring assignees?

Quick answer: The B03AD space is dominated by legacy manufacturers and generics, with patent estates concentrated around individual branded products and their specific formulations, rather than around the actives.

How patent concentration tends to look for this category

A given branded combination product often has:
- 1–3 formulation patents
- 1–2 process patents
- a smaller set of method-of-use claims
Multiple versions across markets can create parallel estates tied to different salts, strengths, or release systems.

Recurring assignee patterns (category-level)

Across iron plus folate combination medicines, assignees typically include:

originator-brand manufacturers that developed specific fixed-dose products
mid-size pharma that licensed branded formulations regionally
generics that hold process/formulation patents for their own approved combinations

Because patent coverage is product- and strength-specific, market participants track estates at the NDC/strength level (US) or the marketing authorization level (EU).

What is the Orange Book status of iron plus folic acid products in the US?

Quick answer: In the US, the Orange Book status is the primary gate for whether generics can launch freely or must clear patent litigation risk. For many B03AD products, Orange Book coverage is limited to a small set of formulation or method patents tied to the NDA/ANDA reference listed drug.

What to check on the Orange Book for B03AD entries

For each RLD (reference listed drug) in iron plus folic acid:

listed drug substance and drug product patents
listed method-of-use patents, if any
patent expiry dates and whether patents are:
- active
- expired
- removed
- subject to PTA/SPC-like adjustments via US patent term adjustments (PTA)

How Orange Book listings translate to launch timing

If no active Orange Book patents remain, ANDA applicants can typically launch at ANDA approval.
If active listed patents remain, applicants either:
- wait for expiration
- file Paragraph IV certifications and litigate
- settle into a controlled launch design (often with a future entry date tied to non-infringement or “no further activity” constraints)

When does exclusivity expire for iron plus folic acid combination drugs?

Quick answer: Exclusivity in this category generally consists of a mix of:

generic-era patent expirations for formulation rights
older NDA exclusivity, if a product was still under exclusivity at initial approval (rare for long-established combinations)
patent term and patent adjustments, which dominate modern entry timing

What drives exclusivity more than data exclusivity?

For B03AD:

fixed-dose combinations rarely rely on long-lived regulatory exclusivity once generics exist for the actives
the controlling factor is usually patent estate rather than regulatory exclusivity

Practical timing logic for generic strategy

A generic entrant’s launch date is typically the earliest of:
1. patent expiry for the last relevant listed patent
2. settlement agreement entry date
3. final disposition of litigation affecting a Paragraph IV patent list
4. any pediatric exclusivity extensions (if applicable) tied to the reference product’s approval and timing

Which patents are most often challenged via Paragraph IV for iron plus folic acid?

Quick answer: Paragraph IV challenges typically target formulation and method-of-use patents that are asserted as covering the approved fixed-dose combination. Most challenges focus on:

non-infringement (differences in ratios, excipients, processing)
invalidity (anticipation/obviousness)

What tends to make a patent “Paragraph IV ready” in this space?

narrow claims to a specific formulation feature
clear listed drug association
lack of enforceable claim scope broad enough to cover typical generic compositions

What tends to make a patent harder to design around?

claims tied to a particular dissolution profile or stability requirement
process claims tied to manufacturing steps that are difficult to replicate without triggering infringement
method-of-use claims that map directly to dosing in the label

What generic entry risks exist for iron plus folic acid combinations?

Quick answer: Entry risk is a function of (1) Orange Book remaining patents, (2) whether an ANDA is certified to those patents via Paragraph IV, and (3) the availability of a design-around formulation that avoids claim coverage while still meeting dissolution and stability requirements.

Key risk vectors for generic manufacturers

Remaining listed patents
- if active, they create litigation risk that can delay launch even after ANDA approval
Design-around constraints
- formulation changes can trigger infringement or failure to meet bioequivalence and dissolution requirements
Stability and manufacturing constraints
- folate is prone to degradation under moisture/heat; generic stability data and process controls must match label shelf-life expectations
Label alignment
- method-of-use claims can narrow permissible label positioning; if a label is challenged, the generic may be forced to pursue labeling carve-outs

How do iron plus folic acid products compare on formulation IP and litigation likelihood?

Quick answer: Within B03AD, IP and litigation risk varies more by formulation approach than by actives. Products with sustained-release or moisture-stabilized folate formulation features have higher odds of stronger patent coverage.

Comparative risk by formulation class

Immediate-release tablets: more likely to have limited patent scope tied to ratio and excipient system
Moisture-protected or stability-optimized products: more likely to have patents that cover processing and packaging
Pediatric liquids: higher chance of process and composition patents due to palatability and stabilizer systems

What patent litigation affects iron plus folic acid combinations?

Quick answer: Litigation in this category is typically driven by:

Orange Book-listed patents for a specific fixed-dose formulation
disputes over whether the ANDA product infringes claims or whether claims are invalid

Typical procedural patterns

Paragraph IV notice triggers suit in the relevant US district court
cases often address:
- claim construction for formulation features
- comparative dissolution curves
- stability and compositional differences
- anticipation/obviousness using earlier iron + folate disclosures

Settlement dynamics (category-level)

When settlements occur:

they often permit a launch date after a defined time rather than immediate entry
they can include restrictions on marketing or continued patent enforcement

How do biosimilar and biologics rules apply to ATC B03AD?

Quick answer: Biosimilar frameworks do not apply. B03AD is a small-molecule iron and folate combination class, not a biologics category.

What formulation patents commonly protect iron plus folic acid tablets and liquids?

Quick answer: The highest-probability formulation patent targets in B03AD are:

iron salt form and polymorph
fixed dose ratio claims
excipient composition that controls dissolution and GI tolerance
moisture and light stabilization of folic acid

Patent claim clusters to map in freedom-to-operate (FTO)

“A tablet comprising” claims with:
- defined percentages of iron salt and folic acid
- specified excipients (binders, disintegrants, lubricants)
dissolution profile claims:
- “wherein the dissolution rate is…” language
process claims:
- “granulating iron salt with excipient under conditions…”
- “coating with polymer selected from…”

Manufacturing method patents and folate stability

Folate stability can drive:

defined packaging and desiccant claims (if tied to patent language)
manufacturing steps controlling moisture content during blending and drying

How does the patent estate differ between iron salts (ferrous sulfate vs other salts) combined with folic acid?

Quick answer: Even within “iron plus folic acid,” separate patents often exist for different iron salt forms because:

solubility and dissolution profiles differ
excipient requirements differ to achieve label specs
stability behavior differs under storage

Practical mapping approach

When analyzing B03AD products:

identify the exact iron salt form and any declared polymorph or hydrate
match to patent claim language around:
- dissolution and disintegration specs
- processing steps and moisture limits
- ratio targets for the fixed-dose combination

Which companies hold the strongest patent positions in iron plus folic acid?

Quick answer: Strength is typically concentrated among firms with:

recent reformulations that received new patents
locally granted process/formulation patents protecting a specific marketed tablet or liquid
Orange Book-listed patents associated with the reference product(s)

Because B03AD is a mature category, “strongest” often means “most recently patented and still listed,” not “broadest composition-of-matter coverage.”

Key takeaways on market dynamics and patent-driven competition for ATC B03AD

Patents matter more than exclusivity: Market entry is usually driven by Orange Book listed patents (US) and product-specific national patent estates (EU and others), not by long-standing data exclusivity.
Formulation is the main IP battleground: Fixed-dose ratio, excipient system, dissolution profile, and folate stability control are the frequent claim targets.
Generic entry hinges on design-around feasibility: Changing ratios, coatings, processing conditions, or dissolution behavior can be required to avoid infringement while meeting FDA specs and shelf-life.
Litigation risk correlates with remaining listed patents: Paragraph IV challenges concentrate on formulation and method-of-use patents associated with the RLD; settlements, when present, typically define a delayed launch date.
Biosimilar frameworks are irrelevant: B03AD is small molecule iron plus folic acid, not biologics.

FAQs

1) What patent claim types most often block ANDA launches for iron plus folic acid?
Formulation “tablet comprising” claims tied to iron salt form, fixed ratios, excipient system, and dissolution profile, plus any method-of-manufacture and label-linked method-of-use claims.

2) Can a generic avoid infringement by switching iron salt forms while keeping folic acid the same?
It can, but infringement risk depends on whether patents claim the salt generically versus specifically, and whether dissolution/stability requirements force similar excipient and processing choices.

3) How do moisture and stability considerations affect generic development for folic acid combinations?
They can force specific processing moisture controls, excipient stabilizers, and packaging choices that may overlap with formulation/process patent claims.

4) What matters most in freedom-to-operate for B03AD beyond active ingredient patents?
Orange Book-listed formulation/process/method-of-use patents tied to the approved strength and dosage form; generic differentiation must be assessed at the formulation and manufacturing level, not just actives.

5) Do settlements in iron plus folic acid cases typically delay launch, and how?
When settlements occur, they generally set an agreed entry date and may limit marketing activities until expiration or other settlement-defined triggers.

References

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-06-28).
European Medicines Agency. EPAR and product information for iron and folic acid fixed-dose combinations. (Accessed 2026-06-28).
World Health Organization. ATC Classification System, ATC B03AD. (Accessed 2026-06-28).

Drugs in ATC Class B03AD

Drugs in ATC Class: B03AD - Iron in combination with folic acid

Market dynamics and patent landscape for ATC Class B03AD (iron with folic acid): exclusivity, Orange Book coverage, and generic entry risk